SAR vs. OBD, C4XD, HEMO, SBTX, OPTI, ONC, DEST, OBI, NSCI, and SNG
Should you be buying Sareum stock or one of its competitors? The main competitors of Sareum include Oxford BioDynamics (OBD), C4X Discovery (C4XD), Hemogenyx Pharmaceuticals (HEMO), SkinBioTherapeutics (SBTX), OptiBiotix Health (OPTI), Oncimmune (ONC), Destiny Pharma (DEST), Ondine Biomedical (OBI), NetScientific (NSCI), and Synairgen (SNG). These companies are all part of the "biotechnology" industry.
Oxford BioDynamics (LON:OBD) and Sareum (LON:SAR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation, community ranking and profitability.
Sareum has a consensus price target of GBX 304, indicating a potential upside of 665.74%. Given Oxford BioDynamics' higher possible upside, analysts clearly believe Sareum is more favorable than Oxford BioDynamics.
Oxford BioDynamics has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Comparatively, Sareum has a beta of -0.79, suggesting that its share price is 179% less volatile than the S&P 500.
36.5% of Oxford BioDynamics shares are owned by institutional investors. 15.7% of Oxford BioDynamics shares are owned by company insiders. Comparatively, 4.0% of Sareum shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Sareum had 1 more articles in the media than Oxford BioDynamics. MarketBeat recorded 1 mentions for Sareum and 0 mentions for Oxford BioDynamics. Oxford BioDynamics' average media sentiment score of 0.36 beat Sareum's score of 0.00 indicating that Sareum is being referred to more favorably in the news media.
Sareum's return on equity of -250.52% beat Oxford BioDynamics' return on equity.
Oxford BioDynamics received 22 more outperform votes than Sareum when rated by MarketBeat users. However, 66.13% of users gave Sareum an outperform vote while only 61.90% of users gave Oxford BioDynamics an outperform vote.
Sareum has lower revenue, but higher earnings than Oxford BioDynamics. Sareum is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.
Summary
Oxford BioDynamics and Sareum tied by winning 8 of the 16 factors compared between the two stocks.
Get Sareum News Delivered to You Automatically
Sign up to receive the latest news and ratings for SAR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
